Business
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical
About this update from Nuvectis Pharma, Inc.
[{"type":"text","content":"Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida. Presentation details are below: Abstract Titles and PresentersPresentation DetailsNXP800Inhibition of HSF1 demonstrates therapeutic efficacy in preclinical models of cholangiocarcinomaPresenter: Danielle M. Carlson Mayo Clinic Hospital-Rochester Rochester, MN, Mayo Clinic Hospital-Rochester Rochester, MNSession Title Genomic and Epigenomic Profiles for Response PredictionSession Type PosterSession Date / Time April 17th, 9AM-12:30PMNXP800Activation of the integrated stress response by the developmental HSF1 pathway inhibitor NXP800Presenter: Marissa V. PowersThe Institute of Cancer Research London, Sutton United KingdomSession Title Late-Breaking Research: Experimental and Molecular Therapeutics 2Session Type PosterSession Date / Time April 18th, 1:30-5PMNXP900In vivo studies demonstrate differences in target inhibition and anticancer efficacy between NXP900 and dasatinib in ovarian clear cell carcinoma modelPresenter: Saúl Navarro-MarchalUniversity of Edinburgh, Edinburgh, United KingdomSession Title Tyrosine Kinase and Phosphatase Inhibitors 2Session Type PosterSession Date / Time April 18th, 9AM-12:30PM About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical stage, oral small molecule currently in a Phase 1a study in patients with advanced solid tumors. NXP800 was granted Fast Track Designation by the United States Food and Drug Administration for the treatment of platinum-resistant, ARID1a-mutated, ovarian carcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor with an IND pending submission. Forward Looking Statements This press release contains \"forward-lo...